NO20052378L - Pre-organiserte trisykliske integraseinhibitorforbindelser - Google Patents

Pre-organiserte trisykliske integraseinhibitorforbindelser

Info

Publication number
NO20052378L
NO20052378L NO20052378A NO20052378A NO20052378L NO 20052378 L NO20052378 L NO 20052378L NO 20052378 A NO20052378 A NO 20052378A NO 20052378 A NO20052378 A NO 20052378A NO 20052378 L NO20052378 L NO 20052378L
Authority
NO
Norway
Prior art keywords
inhibitor compounds
integrase inhibitor
compounds
aryl
organized
Prior art date
Application number
NO20052378A
Other languages
English (en)
Other versions
NO20052378D0 (no
Inventor
Choung U Kim
James M Chen
Xiaowu Chen
Maria Fardis
Haolun Jin
Laura N Schacherer
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of NO20052378D0 publication Critical patent/NO20052378D0/no
Publication of NO20052378L publication Critical patent/NO20052378L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Trisykliske forbindelser ifølge formelen nedenunder, beskyttede mellom- produkter for disse og fremgangsmåter for inhibering av HIV-integrase er beskrevet. Formel (I) Ar L N A^ og A^ er rester som danner en 5-, 6- eller 7-leddet ring..L er en binding eller en linker som forbinder et ring- atom i Ar til N. X er 0, S eller substituert nitrogen. Ar er aryl eller heteroaryl. Q er N, ""NR eller CR''. Aryl- karbonatomene kan uavhengig av hver- andre være substituert med andre substituenter enn hydrogen. Forbindel- sene kan omfatte prolegemiddelrester kovalent bundet på hvilket som helst sted.
NO20052378A 2002-10-16 2005-05-13 Pre-organiserte trisykliske integraseinhibitorforbindelser NO20052378L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41896302P 2002-10-16 2002-10-16
US47878303P 2003-06-16 2003-06-16
PCT/US2003/032666 WO2004035576A2 (en) 2002-10-16 2003-10-16 Pre-organized tricyclic integrase inhibitor compounds

Publications (2)

Publication Number Publication Date
NO20052378D0 NO20052378D0 (no) 2005-05-13
NO20052378L true NO20052378L (no) 2005-07-18

Family

ID=32110203

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052378A NO20052378L (no) 2002-10-16 2005-05-13 Pre-organiserte trisykliske integraseinhibitorforbindelser

Country Status (19)

Country Link
US (3) US20040157804A1 (no)
EP (1) EP1558613A2 (no)
JP (1) JP2006514099A (no)
KR (1) KR20050087787A (no)
CN (1) CN100374438C (no)
AP (1) AP1858A (no)
AU (2) AU2003301439A1 (no)
BR (1) BR0315405A (no)
CA (1) CA2501881A1 (no)
EA (1) EA011399B1 (no)
HR (1) HRP20050431A2 (no)
IS (1) IS7845A (no)
MX (1) MXPA05003950A (no)
NO (1) NO20052378L (no)
NZ (1) NZ539264A (no)
OA (1) OA13079A (no)
PL (1) PL377966A1 (no)
UA (1) UA79830C2 (no)
WO (2) WO2004035577A2 (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4910500A (en) * 1999-05-19 2000-12-12 Neurosearch A/S Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
KR20060006047A (ko) * 2003-04-28 2006-01-18 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ 인테그레이즈 저해제
ATE433974T1 (de) * 2003-09-19 2009-07-15 Gilead Sciences Inc Azachinolinolphosphonatverbindungen als integraseinhibitoren
CA2547418A1 (en) * 2003-12-08 2005-06-23 The Research Foundation Of State University Of New York Site selectively tagged and templated molecularly imprinted polymers for sensor applications
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
US7598087B2 (en) * 2004-01-07 2009-10-06 The Research Foundation Of State University Of New York Protein imprinted polymers with integrated emission sites
ES2315922T3 (es) * 2004-04-14 2009-04-01 Gilead Sciences, Inc. Analogos de fosfonato de compuestos inhibidores de la integrasa del vih.
CA2564372C (en) * 2004-05-07 2011-10-11 Merck & Co., Inc. Hiv integrase inhibitors
AU2005251820A1 (en) * 2004-06-09 2005-12-22 Merck & Co., Inc. HIV integrase inhibitors
US7745459B2 (en) 2004-09-21 2010-06-29 Japan Tobacco Inc. Quinolizinone compound and use thereof as HIV integrase inhibitor
JP2008516973A (ja) 2004-10-15 2008-05-22 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
TW200716632A (en) * 2005-05-16 2007-05-01 Gilead Sciences Inc Integrase inhibitor compounds
AU2006246930C1 (en) 2005-05-19 2012-01-19 Merck Canada Inc. Quinoline derivatives as EP4 antagonists
CA2616314A1 (en) * 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of hiv
JP2009503089A (ja) * 2005-08-04 2009-01-29 スミスクライン ビーチャム コーポレーション Ｈｉｖインテグラーゼ阻害薬
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20080039487A1 (en) * 2005-12-21 2008-02-14 Gilead Sciences, Llc Processes and intermediates useful for preparing integrase inhibitor compounds
US20070219243A1 (en) 2005-12-30 2007-09-20 Kearney Brian P Method for improving the pharmacokinetics of HIV integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090306054A1 (en) 2006-05-16 2009-12-10 Gilead Sciences ,Inc. Integrase inhibitors
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
WO2009067541A2 (en) * 2007-11-20 2009-05-28 Gilead Sciences, Inc. Integrase inhibitors
CN101977610B (zh) 2008-01-25 2012-05-16 奇默里克斯公司 治疗病毒感染的方法
EP2660239B1 (en) 2008-07-25 2016-11-23 VIIV Healthcare Company Chemical compounds as synthetic intermediates
MX2011000971A (es) * 2008-07-28 2011-06-24 Polymedix Inc Compuestos antipaludicos.
CN102245572B (zh) 2008-12-11 2015-03-25 盐野义制药株式会社 氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体
SG171308A1 (en) 2008-12-11 2011-07-28 Shionogi & Co Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
EP2270021A1 (en) * 2009-06-18 2011-01-05 Centre National de la Recherche Scientifique Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
CN102574854B (zh) 2009-10-13 2014-04-16 伊兰科动物健康爱尔兰有限公司 大环整合酶抑制剂
JP5745869B2 (ja) * 2010-01-22 2015-07-08 富山化学工業株式会社 アルアルキル基を有する複素環化合物
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
PT2534150T (pt) 2010-02-12 2017-05-02 Chimerix Inc Métodos para tratar uma infecção viral
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
TWI503323B (zh) * 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
EP2552923B1 (en) 2010-04-02 2014-03-26 Janssen R&D Ireland Macrocyclic integrase inhibitors
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
EP3750544A3 (en) 2011-11-30 2021-03-24 Emory University Jak inhibitors for use in the prevention or treatment of viral infection
KR101365849B1 (ko) * 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
BR112017013858A2 (pt) 2014-12-26 2018-02-27 Univ Emory n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos
BR112017015693A2 (pt) 2015-02-03 2018-03-20 Pfizer ciclopropabenzofuranil piridopirazinadionas
CN104803905B (zh) * 2015-04-17 2017-10-10 复旦大学 一种合成异吲哚啉‑1‑酮衍生物的方法
WO2017133517A1 (zh) * 2016-02-03 2017-08-10 四川海思科制药有限公司 一种磷酰胺衍生物及制备方法和用途
CN109305990B (zh) * 2017-07-28 2021-02-26 四川海思科制药有限公司 一种磷酸衍生物及制备方法和用途
CN109305989B (zh) * 2017-07-28 2021-02-26 四川海思科制药有限公司 一种磷酰胺衍生物及制备方法和用途
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH385846A (de) * 1960-03-31 1964-12-31 Geigy Ag J R Verfahren zur Herstellung von neuen 7-Acyl-8-hydroxy-chinolinen und ihre Verwendung als Fungizide und Bakterizide im Pflanzen- und Materialschutz
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DK0533833T3 (da) 1990-06-13 1996-04-22 Arnold Glazier Phosphorprolægemidler
ES2118069T3 (es) * 1990-09-14 1998-09-16 Acad Of Science Czech Republic Profarmacos de fosfonatos.
EP0498722B1 (fr) * 1991-02-07 1997-07-30 Roussel Uclaf Dérivés bicycliques azotés, leur procédé de préparation, les intermédiaires obtenus, leur application comme médicaments et les compositions pharmaceutiques les renfermant
EP0520573A1 (en) * 1991-06-27 1992-12-30 Glaxo Inc. Cyclic imide derivatives
US5639881A (en) * 1991-11-08 1997-06-17 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis and elucidation of pyrimido (4,5-Q) quinazoline derivatives
TW304945B (no) * 1992-06-27 1997-05-11 Hoechst Ag
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5538988A (en) * 1994-04-26 1996-07-23 Martinez; Gregory R. Benzocycloalkylazolethione derivatives
US5854275A (en) * 1996-05-16 1998-12-29 Pfizer Inc. Cyclic imide derivatives
JP2002505660A (ja) * 1996-09-10 2002-02-19 ファルマシア・アンド・アップジョン・カンパニー 抗ウィルス剤としての８―ヒドロキシ―７―置換キノリン
WO1999007701A1 (en) * 1997-08-05 1999-02-18 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
AU4225499A (en) 1998-06-03 1999-12-20 Merck & Co., Inc. Hiv integrase inhibitors
WO1999062513A1 (en) 1998-06-03 1999-12-09 Merck & Co., Inc. Hiv integrase inhibitors
MXPA00012248A (es) * 1998-06-10 2003-04-25 Arena Pharm Inc Incrementadores de acetilcolina.
US6187907B1 (en) * 1998-08-31 2001-02-13 James Chen Triple helix coil template having a biologically active ligand
AU3118200A (en) 1998-12-14 2000-07-03 Merck & Co., Inc. Hiv integrase inhibitors
ID29027A (id) 1998-12-25 2001-07-26 Shionogi & Co Turunan-turunan heteroaromatik yang mempunyai aktivitas penghambatan terhadap integrase hiv
AU763231B2 (en) 1999-06-02 2003-07-17 Shionogi & Co., Ltd. Novel processes for the preparation of substituted propenone derivatives
EP1196384A4 (en) 1999-06-25 2002-10-23 Merck & Co Inc 1- (AROMATIC OR HETEROAROMATICALLY SUBSTITUTED) -3- (HETEROAROMATICALLY SUBSTITUTED) -1,3-PROPANDIONS AND THEIR APPLICATIONS
US6245806B1 (en) 1999-08-03 2001-06-12 Merck & Co., Inc. HIV integrase inhibitors
AU8009900A (en) * 1999-10-13 2001-04-23 Merck & Co., Inc. Hiv integrase inhibitors
JP2004517860A (ja) 2000-10-12 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
NZ525088A (en) * 2000-10-12 2004-11-26 Merck & Co Inc Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
US6919351B2 (en) * 2000-10-12 2005-07-19 Merck & Co., Inc. Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
WO2002036734A2 (en) 2000-10-12 2002-05-10 Merck & Co., Inc. Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
AU2002215018A1 (en) * 2000-10-13 2002-04-22 Bayer Aktiengesellschaft Human histone deacetylase gene
US6518767B1 (en) * 2000-10-19 2003-02-11 Schweitzer Engineering Laboratories, Inc. Line differential protection system for a power transmission line
ES2315922T3 (es) * 2004-04-14 2009-04-01 Gilead Sciences, Inc. Analogos de fosfonato de compuestos inhibidores de la integrasa del vih.

Also Published As

Publication number Publication date
KR20050087787A (ko) 2005-08-31
US20040167124A1 (en) 2004-08-26
US20090029939A1 (en) 2009-01-29
PL377966A1 (pl) 2006-02-20
WO2004035577A3 (en) 2004-07-29
WO2004035577A2 (en) 2004-04-29
US7253180B2 (en) 2007-08-07
CN1726212A (zh) 2006-01-25
JP2006514099A (ja) 2006-04-27
AU2003301439A1 (en) 2004-05-04
EP1558613A2 (en) 2005-08-03
UA79830C2 (en) 2007-07-25
MXPA05003950A (es) 2005-06-17
AP2005003279A0 (en) 2005-06-30
US20040157804A1 (en) 2004-08-12
OA13079A (en) 2006-11-10
HRP20050431A2 (en) 2005-10-31
CA2501881A1 (en) 2004-04-29
IS7845A (is) 2005-05-13
WO2004035576A3 (en) 2004-06-24
EA011399B1 (ru) 2009-02-27
AU2003301306A1 (en) 2004-05-04
AU2003301439A8 (en) 2004-05-04
CN100374438C (zh) 2008-03-12
NO20052378D0 (no) 2005-05-13
WO2004035576A2 (en) 2004-04-29
NZ539264A (en) 2007-08-31
AP1858A (en) 2008-06-30
BR0315405A (pt) 2005-08-09
EA200500660A1 (ru) 2005-10-27

Similar Documents

Publication Publication Date Title
NO20052378L (no) Pre-organiserte trisykliske integraseinhibitorforbindelser
DE602004021611D1 (de) Azachinolinolphosphonatverbindungen als integraseinhibitoren
WO2009074749A3 (fr) Dérives de nicotinamide. leur préparation et leur application en thérapeutique
TW200800988A (en) Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
WO2003087087A3 (en) Heterocyclic compounds and their use as modulators of p38 map kinase
WO2006109075A3 (en) Hydroxybenzamide derivatives and their use as inhibitors of hsp90
WO2002042292A3 (en) Indol derivative and their use as inhibitors of p38 kinase
IL204594A (en) Protein kinase inhibitors
BG106091A (en) INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
TW200740820A (en) Fused heterocyclic derivatives and use thereof
DE60232065D1 (de) Indol-, azaindol- und verwandte heterozyklische amidopiperazin-derivate
DK0804427T3 (da) LTA4-hydrolaseinhibitorer
WO2009072581A1 (ja) ラクタム化合物又はその塩及びｐｐａｒ活性化剤
HUP0302997A2 (hu) alfa4-Integrin antagonista hatású fenilalanin-származékok, azokat tartalmazó gyógyászati készítmények és alkalmazásuk
UA96568C2 (en) Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
NO20042584L (no) Dibenzylaminforbindelser og farmasoytisk anvendelse derav
WO2009016841A1 (ja) オキソピラジン誘導体及び除草剤
TW200621759A (en) Novel aminopyridine derivatives having aurora A selective inhibitory action
WO2006012395A3 (en) Peptidase inhibitors
EA200971063A1 (ru) Ариламидпиримидоновые соединения
TW200745104A (en) Multikinase inhibitor
WO2005061476A3 (en) Aroylfuranes and aroylthiophenes
AU2003207432A1 (en) Urea linker derivatives for use as ppar modulators
EP1364950A4 (en) PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE
NO20063057L (no) Nitrooksyderivater av carvedilol og andre betablokkere som antihypertensive legemidler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application